English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/96816
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 4 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título

Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis

Autor Moneo, Victoria; Serelde, Beatriz G.; Blanco-Aparicio, Carmen; Diaz-Uriarte, Ramon; Avilés, Pablo; Santamaría, Gemma; Tercero, Juan C.; Cuevas, Carmen; Carnero, Amancio
Fecha de publicación 23-abr-2014
EditorBioMed Central
Citación BMC Cancer 14(1): 281 (2014)
Resumen[Background] Zalypsis® is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing’s sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by selecting those patients more likely to respond to this therapy.
[Methods] Using in vitro drug sensitivity data coupled with a set of molecular data from a panel of sarcoma cell lines, we developed molecular signatures that predict sensitivity to Zalypsis. We verified these results in culture and in vivo xenograft studies.
[Results] Zalypsis resistance was dependent on the expression levels of PDGFRα or constitutive phosphorylation of c-Kit, indicating that the activation of tyrosine kinase receptors (TKRs) may determine resistance to Zalypsis. To validate our observation, we measured the levels of total and active (phosphorylated) forms of the RTKs PDGFRα/β, c-Kit, and EGFR in a new panel of diverse solid tumor cell lines and found that the IC50 to the drug correlated with RTK activation in this new panel. We further tested our predictions about Zalypsis determinants for response in vivo in xenograft models. All cells lines expressing low levels of RTK signaling were sensitive to Zalypsis in vivo, whereas all cell lines except two with high levels of RTK signaling were resistant to the drug.
[Conclusions] RTK activation might provide important signals to overcome the cytotoxicity of Zalypsis and should be taken into consideration in current and future clinical trials.
Versión del editorhttp://dx.doi.org/10.1186/1471-2407-14-281
URI http://hdl.handle.net/10261/96816
DOI10.1186/1471-2407-14-281
E-ISSN1471-2407
Aparece en las colecciones: (IBIS) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
1471-2407-14-281.xml80,72 kBXMLVisualizar/Abrir
1471-2407-14-281-S2.doc77 kBMicrosoft WordVisualizar/Abrir
1471-2407-14-281.pdf1,27 MBAdobe PDFVista previa
Visualizar/Abrir
1471-2407-14-281-S3.doc89,5 kBMicrosoft WordVisualizar/Abrir
1471-2407-14-281-S1.doc76 kBMicrosoft WordVisualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.